Abstracts of the 2023 Annual Meeting of the ALEH
More infoCirrhotic cardiomyopathy (CCM) is a complication of cirrhosis associated with increased risk of postoperative complications related to liver transplantation (LT). Its first manifestations are habitually unspecified and can be seen throughout stress situations. Its criteria were recently updated without studies of its prevalence in our population. This study aimed to characterized the population with cirrhotic cardiomyopathy according to the new proposal criteria and evaluate the development of complications associated with liver transplantation.
Materials and MethodsA retrospective observational study in adult patients with cirrhosis after liver transplantation (2017-2022) with pre-liver transplantation echocardiogram available. It was determined CCM according to the Cirrhotic Cardiomyopathy Consortium 2020 considered as criteria of systolic dysfunction the presence of LVEF < 50% and diastolic dysfunction (DD) the presence of 3/4 of the following criteria (septal e’ velocity < 7 cm/s, E /e’ > 15, left atrial volume index (LAVI) > 34 ml/m2 and tricuspid velocity > 2.8 m/s).
ResultsDuring the study period, 82 patients met inclusion criteria, of whom 8 (10%) fulfilled criteria for CMC. There were no patients with systolic dysfunction. In patients with CMC, it was observed a tendency, not significant, to higher complications of hepatorenal syndrome, heart failure and mortality post-liver transplantation. If we extend the definition of DD to only 2 of 4 criteria, the prevalence of CMC increased to 31%. Considering the latter classification, it was observed an increase in dialysis needs post-liver transplantation (36% vs. 14%; p = 0.03) and a non-significant higher development of cardiac insufficiency (20% vs. 9%; p = 0.164).
ConclusionsThe CMC is frequent in cirrhotic patients’ candidates to liver transplantation (10%). Its presence could imply higher risk of complications pre and post-liver transplantation.
